Lu AG13909 for Cushing's Disease

(BalanCeD Trial)

This trial explores a new treatment called Lu AG13909 for individuals with Cushing's disease, a condition characterized by excessive cortisol production. The trial aims to assess how Lu AG13909 affects cortisol levels, its safety and tolerability, and how the body processes the drug. Participants will receive the treatment first through an IV and then under the skin. Ideal candidates are generally healthy individuals with confirmed Cushing's disease, except for well-managed related health issues like diabetes or high blood pressure. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group of participants.

If you are taking medication for high cortisol levels due to Cushing's disease, you will need to stop taking them for a certain period before the trial begins. This is called a washout period (time without taking certain medications).

Research has shown that Lu AG13909 was tested in early studies using lab models. It successfully reduced hormone levels, such as cortisol, without reported side effects. This suggests the treatment might be easy for people to tolerate. However, since this trial is in its early stages, more information from human participants is needed to fully understand its safety.¹²³⁴⁵

Lu AG13909 is unique because it offers a new approach to managing Cushing's Disease. Unlike standard treatments, which often involve surgery or medications that inhibit cortisol production indirectly, Lu AG13909 is designed to directly target the body's mechanisms that cause the excessive production of cortisol. Researchers are particularly excited about its dual delivery method, initially administered intravenously and then switched to a subcutaneous injection, which could provide flexible and sustained management of symptoms. This innovative approach could potentially offer a more effective and user-friendly option for patients struggling with this challenging condition.

Research has shown that Lu AG13909, the investigational treatment in this trial, is designed to lower cortisol levels in people with Cushing's disease. This disease causes excessive cortisol production, leading to weight gain, high blood pressure, and other health issues. Early findings suggest that Lu AG13909 may effectively reduce cortisol production, potentially managing these symptoms. Although specific data on Lu AG13909's effectiveness in humans is limited, it aims to lower cortisol levels and may offer relief to those with the condition.⁶⁷⁸⁹¹⁰